The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans

García-Rodríguez, Julio César; Testé, Iliana Sosa

doi:10.1100/tsw.2009.103

Cited by 55 publications

(45 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Borneol has been mainly used to treat cardiovascular system diseases and encephalopathy in clinical therapy (Garcia-Rodriguez and Sosa-Teste, 2009). Traditional medicine prescriptions are administered mostly by oral route; some effective components are absorbed through gastroenterological mucous membrane, and some enter the blood circulation system and permeated BBB to perform their functions.…”

Section: Discussionmentioning

confidence: 99%

Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations

Zhao

et al. 2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Borneol, a monoterpenoid alcohol, is used widely, particularly in combined formulas for preventing and curing cardiovascular and cerebrovascular diseases in traditional Chinese medicine. In order to understand the blood and brain pharmacokinetics after intravenous, intranasal, or oral administration and to investigate the superiority and feasibility of intranasal administration, a simple gas chromatographic (GC) method with flame ionization detection (FID) was developed for the quantification of borneol. Blood samples and brain were collected from mice at 1, 3, 5, 10, 20, 30, 60, 90, and 120 min after intravenous, intranasal, or oral administration of borneol at a dosage of 30.0 mg/kg. Sample preparations were carried out by liquid-liquid extraction with an internal standard solution of octadecane. The pharmacokinetic parameters were calculated by the software of Kinetica. The calibration curves were linear in the range of 0.11-84.24 μg/ml and 0.16-63.18 μg/g for borneol in plasma and brain, respectively. The methodological and extraction recoveries were both in the range of 85%-115%. The intra-day and inter-day variabilities for plasma and brain samples were ≤5.00% relative standard deviation (RSD). The absolute bioavailabilities F of intranasal and oral administrations were 90.68% and 42.99%. The relative brain targeted coefficients Re of intranasal and oral administrations were 68.37% and 38.40%. The GC-FID method developed could be applied to determination and pharmacokinetic study. The borneol from injection was distributed and metabolized fast without absorption process. The borneol from oral administration was distributed more slowly and had the lowest absolute bioavailability. Nasal administration of borneol was quickly absorbed into the blood and brain, was easy to use and had a greater safety than infection, which makes it worthy of further development as an administration route for encephalopathy treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations

Zhao

et al. 2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…Nonerythropoietic EPO derivatives include the mutants EpoR76E and EpoS71E (see [22]), carbamylated EPO (CEPO), EPO with low or no sialylation (neuro-EPO and asialoEPO, resp.) [23], and the peptides pHBSP/ARA290 [24, 25] and Epotris [26]. …”

Section: Introductionmentioning

confidence: 99%

Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects

Dmytriyeva

Pankratova

Korshunova

et al. 2016

Mediators of Inflammation

View full text Add to dashboard Cite

The cytokine erythropoietin (EPO) stimulates proliferation and differentiation of erythroid progenitor cells. Moreover, EPO has neuroprotective, anti-inflammatory, and antioxidative effects, but the use of EPO as a neuroprotective agent is hampered by its erythropoietic activity. We have recently designed the synthetic, dendrimeric peptide, Epobis, derived from the sequence of human EPO. This peptide binds the EPO receptor and promotes neuritogenesis and neuronal cell survival. Here we demonstrate that Epobis in vitro promotes neuritogenesis in primary motoneurons and has anti-inflammatory effects as demonstrated by its ability to decrease TNF release from activated AMJ2-C8 macrophages and rat primary microglia. When administered systemically Epobis is detectable in both plasma and cerebrospinal fluid, demonstrating that the peptide crosses the blood-brain barrier. Importantly, Epobis is not erythropoietic, but systemic administration of Epobis in rats delays the clinical signs of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis, and the peptide has long-term, but not short-term, effects on working memory, detected as an improved social memory 3 days after administration. These data reveal Epobis to be a nonerythropoietic and neuroprotective EPO receptor agonist with anti-inflammatory and memory enhancing properties.

show abstract

“…In addition to their immunostimulatory activity, CpG-ODN display various drug-like characteristics, including high water solubility, ease of chemical synthesis on a large scale, and high stability and biodegradability [33,46]. Intranasal drug administration may enable rapid drug absorption and eliminate its liver peripheral removal without inducing systemic side effects [47]. In addition, the delivery of CpG-ODN via the nose is expected to be safe, convenient, and well tolerated [33] and protects the CpG-ODN from degradation by DNases [48].…”

mentioning

confidence: 99%

Intranasal administration of CpG oligodeoxynucleotides reduces lower airway inflammation in a murine model of combined allergic rhinitis and asthma syndrome

Zhang

Chen

et al. 2015

International Immunopharmacology

View full text Add to dashboard Cite

The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans

Cited by 55 publications

References 90 publications

Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations

Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations

Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects

Intranasal administration of CpG oligodeoxynucleotides reduces lower airway inflammation in a murine model of combined allergic rhinitis and asthma syndrome

Contact Info

Product

Resources

About